<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:7pt Arial, sans-serif; }
 .font1 { font:8pt Arial, sans-serif; }
 .font2 { font:14pt Arial, sans-serif; }
 .font3 { font:10pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font2">J.P. Morgan</span></p>
<p><span class="font1" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font0" style="font-weight:bold;">07 September 2016</span></p>
<p><span class="font0" style="font-weight:bold;">Isabella Y. Zhao, CFA</span></p>
<p><span class="font0" style="font-weight:bold;">(852) 2800-8534</span></p>
<p><a href="mailto:isabella.zhao@jpmorgan.com"><span class="font0" style="font-weight:bold;">isabella.zhao@jpmorgan.com</span></a></p>
<p><span class="font3" style="font-weight:bold;">Analyst Certification: </span><span class="font3">The research analyst(s) denoted by an “AC” on the cover of this report certifies (or, where multiple research analysts are primarily responsible for this report, the research analyst denoted by an “AC” on the cover or within the document individually certifies, with respect to each security or issuer that the research analyst covers in this research) that: (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers; and (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. For all Korea-based research analysts listed on the front cover, they also certify, as per KOFI A requirements, that their analysis was made in good faith and that the views reflect their own opinion, without undue influence or intervention.</span></p>
<p><span class="font3" style="font-weight:bold;">Important Disclosures</span></p>
<ul style="list-style:none;"><li>
<p><span class="font3" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Market Maker/ Liquidity Provider: </span><span class="font3">J.P. Morgan Securities plc and/or an affiliate is a market maker and/or liquidity provider in securities issued by Sinopharm.</span></p></li>
<li>
<p><span class="font3" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Beneficial Ownership (1% or more): </span><span class="font3">J.P. Morgan beneficially owns 1% or more of a class of common equity securities of Sinopharm.</span></p></li>
<li>
<p><span class="font3" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Client: </span><span class="font3">J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients: Sinopharm.</span></p></li>
<li>
<p><span class="font3" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Client/Non-Investment Banking, Securities-Related: </span><span class="font3">J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients, and the sendees provided were non-investment-banking, securities-related: Sinopharm.</span></p></li>
<li>
<p><span class="font3" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Client/Non-Securities-Related: </span><span class="font3">J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients, and the sendees provided were non-securities-related: Sinopharm.</span></p></li>
<li>
<p><span class="font3" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Non-Investment Banking Compensation: </span><span class="font3">J.P. Morgan has received compensation in the past 12 months for products or sendees other than investment banking from Sinopharm.</span></p></li>
<li>
<p><span class="font3" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Other Significant Financial Interests: </span><span class="font3">J.P. Morgan owns a position of 1 million USD or more in the debt securities of Sinopharm.</span></p></li>
<li>
<p><span class="font3">• &nbsp;&nbsp;&nbsp;MSCI: The MSCI sourced information is the exclusive property of MSCI. Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an 'as is' basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI and tire MSCI indexes are sendees marks of MSCI and its affiliates.</span></p></li></ul>
<p><span class="font3" style="font-weight:bold;">Company-Specific Disclosures: </span><span class="font3">Important disclosures, including price charts and credit opinion history tables, are available for compendium reports and all J.P. Morgan-covered companies by visiting </span><a href="https://jpmm.com/research/disclosures"><span class="font3" style="text-decoration:underline;">https://jpmm.com/research/disclosures</span></a><span class="font3" style="text-decoration:underline;">,</span><span class="font3"> calling 1-800-477-0406, or e-mailing </span><a href="mailto:research.disclosure.inquiries@jpmorgan.com"><span class="font3" style="text-decoration:underline;">research.disclosure.inquiries@jpmorgan.com</span></a><span class="font3"> with your request. J.P. Morgan’s Strategy, Technical, and Quantitative Research teams may screen companies not covered by J.P. Morgan. For important disclosures for these companies, please call 1-800-477-0406 or e-mail </span><a href="mailto:research.disclosure.inquiries@jpmorgan.com"><span class="font3" style="text-decoration:underline;">research.disclosure.inquiries@jpmorgan.com</span></a><span class="font3">.</span></p>
<p><span class="font0" style="font-weight:bold;">27</span></p>
</body>
</html>